John Jacobs hops from Harmony to head up Novavax

10 January 2023

Shares of Novavax (Nasdaq: NVAX) closed up 11.25% at $12.26 yesterday after it announced a successor for its president and chief executive Stanley Erck, who plans to retire.

At a time when the COVID-19 vaccine maker looks to catch up with larger rivals, Novavax said it has appointed John Jacobs to take up both these positions, and he will become a member of the board of directors. The transition will be effective as of January 23, 2023. Mr Erck will serve as an advisor to the company for the next fifteen months to enable a smooth transition.

"As we prepare for Stan's retirement, the board reflects on the incredible legacy he leaves behind," said Novavax chairman James Young, adding: "Stan led Novavax from a clinical development organization to a global commercial vaccines company during a worldwide pandemic. This foundation puts Novavax in a strong position to execute on its long-term strategy, and we look forward to supporting Stan and John through the transition. John is a seasoned industry leader who will bring a fresh perspective and deep industry expertise to Novavax."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK